p 5

BMS-P5 is a specific and orally active Peptidylarginine Deiminase 4 (PAD4) inhibitor.

BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor that blocks the formation of Neutrophil Extracellular Traps and delays the progression of multiple myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays symptom onset and disease progression. Targeting PAD4 may be beneficial for treating multiple myeloma.

p5 Ligand for Dnak and DnaJ is a nonapeptide corresponding to the primary binding sites of the 23-residue mitochondrial aspartate aminotransferase presequence. p5 ligand is a high-affinity ligand for Dnak and DnaJ.

p5 Ligand for Dnak and DnaJ acetate is a nonapeptide. It is a high-affinity ligand for DnaK (E. coli Hsp70) and DnaJ (E. coli Hsp40).

MTvkPABC-P5d TFA, a TLR7 agonist, functions as an immune stimulant. It is applicable in the synthesis of immune-stimulating antibody conjugates (ISAC).

P5(PEG12)-VC-PAB-Exatecan (LP3) is an integral part of a drug-linker conjugate for ADC, formed by linking P5(PEG24)-VC-PAB with the DNA topoisomerase I inhibitor, Exatecan. It is utilized in the preparation of antibody-drug conjugates (ADC) and employed in tumor research.

Aseanostatin P5 inhibits myeloperoxidase (MPO) release from human polymorphonuclear leukocytes.

MTvkPABC-P5d, functioning as a TLR7 agonist, serves as an immune stimulant and is utilized in the synthesis of immune-stimulating antibody conjugates (ISACs) [1].

Pardaxin P5, an antimicrobial peptide, inhibits Escherichia coli at a minimum inhibitory concentration (MIC) of 13 μM [1].

P5(PEG24)-VC-PAB-exatecan, a camptothecin-based linker-payload platform, utilizes the highly potent derivative exatecan. This compound features linker-payload structures and is primarily employed in the research of tumor [1].

Exendin-P5, a selective agonist for GLP-1R, enhances the potency of G protein-mediated signaling through rapid activation of G proteins via transient interactions with the GLP-1R transmembrane domain. This action accelerates cAMP production, pointing to Exendin-P5's potential use in researching metabolic diseases.

Pardaxin P5TFA is the TFA salt form of Pardaxin P5. This compound is an antimicrobial peptide with a MIC value of 13 μM against Escherichia coli.

Ethanol, 2,2'-((p-(5-phenylpentyloxy)phenyl)imino)di- is a bioactive chemical.

Ethylenediamine, N,N-diethyl-N'-(p-(5-phenoxypentyloxy)phenyl)- is a bioactive chemical.

[Glp5] Substance P (5-11), an octapeptide, is a key fragment of substance P in the rat central nervous system (CNS) and plays a localized role in modulating dopamine release in the rat striatum [1].

[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is an analogue of Substance P that acts on the neurokinin 1 receptor (NK1R) in rat brain, similarly to Substance P but with a significantly extended duration of action. This compound selectively enhances dopamine metabolism within the mesencephalon and midbrain cortex, increases motor activity, and facilitates the resumption of addictive agent-seeking behavior in rats [1] [2] [3].

[Glp5,Sar9] Substance P (5-11) is an analogue of Substance P [1].

[Asp5,6,Me-Phe8] Substance P (5-11) acts as an NK-3 tachykinin receptor agonist. It is known to reduce alcohol consumption in alcohol-preferring rats.

P5SA-2 is a selective allosteric activator of PPP5C, functioning by modulating the structure of the PPP5C phosphatase domain. At a concentration of 100 μM, it can enhance PPP5C activity by 3.2-fold, with an apparent affinity constant of 7.8 μM. P5SA-2 is applicable in research related to cancer and Alzheimer's disease.

D-myo-Inositol-1,3,4,5,6-pentaphosphate (ammonium salt) [Ins(1,3,4,5,6)P5 (ammonium salt)] is an isomer of inositol phosphate that functions as a small, soluble second messenger in cellular signaling. It can bind to the PH domain of Grp1 with a dissociation constant (Kd) of 590 nM. This compound inhibits the phosphorylation and kinase activity of Akt/PKB, leading to apoptosis in ovarian, lung, and breast cancer cells. Additionally, it exhibits anti-angiogenic activity in vitro, blocking capillary formation by HUVECs, and demonstrates antitumor effects in cancer xenograft models in nude mice.

D-myo-Inositol-1,2,4,5,6-pentaphosphate (Ins(1,2,4,5,6)P5) sodium salt is one of several inositol polyphosphate isomers involved in signal transduction. In human Jurkat T lymphocytes, Ins(1,2,4,5,6)P5 (sodium salt) is phosphorylated by 1/3 kinase to form InsP6. This compound plays a role in calcium signaling pathways.

D-myo-Inositol-1,2,3,5-tetraphosphate (Ins(1,2,3,5,6)-P5) tetrasodium is one of the inositol phosphate isomers that acts as a soluble second messenger in cellular calcium signaling.

D-myo-Inositol-1,3,4,5,6-pentaphosphate sodium (Ins(1,3,4,5,6)P5 sodium) is an intracellular signaling molecule. It inhibits the PI3K/Akt signaling pathway, suppressing the phosphorylation and kinase activity of Akt/PKB, which induces apoptosis in cancer cells. Additionally, it inhibits endothelial cell tubular structure formation in an in vitro angiogenesis mouse model. This compound is employed in research on ovarian cancer, lung cancer, breast cancer, and cardiovascular diseases involving angiogenesis inhibition.

FAUC 213 is a selective full antagonist of the dopamine D4 receptor.